Triple-Drug attack on tough leukemia shows promise but trial halted
NCT ID NCT04435691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of three drugs—magrolimab, azacitidine, and venetoclax—in 110 adults with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find the best dose and see if the combination could put the cancer into remission. However, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
magrolimab, azacitidine, and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong
The trial was terminated early, so results are limited. The combination may cause significant side effects, and it is unclear if it works better than existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States